Cannabidiol and palmitoylethanolamide are anti-inflammatory in the acutely inflamed human colon
Laboratory studyHumans
- Design
- Laboratory study
- Subjects
- Caco-2 cell cultures and human colon tissue explants from bowel cancer, inflammatory bowel disease and appendicitis resections
- Dose used in the study
- Palmitoylethanolamide or cannabidiol at 10 micromolar in culture, with an inflammatory stimulus
- Duration
- Tissue culture
- What was measured
- Nine intracellular signalling phosphoproteins; cytokine secretion; receptor antagonist studies
What the authors reported
Palmitoylethanolamide reduced inflammatory signalling in cells and explants and prevented the rise in cytokine release in explant colon, an effect blocked by a PPAR-alpha antagonist. It was anti-inflammatory in both inflammatory bowel disease and appendicitis tissue.
Limits of this study
Tissue culture, not a treatment study. The cytokine effect appeared in explants but not in the cell line. The same group's later human permeability trial is Couch 2019. Independent academic group.
Source
PubMed 28954820 · doi:10.1042/CS20171288
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.